PharmaceuticalOutsourcingQ42020 - 32

CLINICAL TRIALS

lengthy delays and prove extremely costly. Common recruitment

the palms of their hands, patients may have an easier time staying on

and retention obstacles include patients' financial barriers, logistical

track with their trial responsibilities.

concerns, the lack of resources for patients and clinicians and even
a study's own restrictive eligibility criteria.4 Overcoming these
obstacles can improve a study's chances for success and significantly
speed up a trial.

For the study team and sites, remote technology means they no
longer must rely solely on what they can glean from intermittent
clinical visits with patients. They can now have full visibility of patient
behavior, 24/7. This enables them to provide the right level of support

Technology is now available that helps to identify and screen

for patients and get the most out of necessary clinical visits. Patients

potential study candidates. This technology records a variety of

that might need a little more help and oversight can have more time

patient characteristics that can be captured with a smart device and
then analyzes that data to help predict which candidates are likely
to be high performers, meaning they will be more likely to show
high dosing adherence and less likely to drop out of a given study.
Starting a trial with an optimized patient cohort greatly increases the
likelihood of getting better data.

with their clinical providers, while patients that have been extremely
on task can get in and out. Always-on remote technology can provide
the study teams with a wealth of data on each patient, so that
when the patient does come into the clinic, time is not wasted and
caregivers can focus on higher value interactions versus spending
time asking basic questions around things like dosing.

Aside from using technology to build predictive models of cohort
success, it is important to build a plan for how study teams will
communicate with patients via technology. Focusing on the patient
early has clear benefits that affect a study's potential success. For
instance, a recent article published in Health Affairs showed that
having a clear plan for how caregivers will communicate with patients
throughout the trial and sharing that plan with potential study

Conclusion
COVID-19 has changed the way many live their lives and do their
jobs, but there are some unforeseen benefits. Just as many industries
are discovering that productivity and success can be achieved with
a largely remote workforce, we in the clinical trials space are seeing

candidates increased enrollment from 65% to 95%.5

benefits to adopting and implementing remote technologies.

Benefit 2: Patient Engagement

arisen from a concern over keeping trials moving, or being able to

Once the patient pool is set, remote technology can be utilized to

start new trials during the pandemic, numerous benefits of these

While the acceleration of remote technology adoption may have

optimize their performance. With a smart device that they already

technologies have been observed that will continue to be utilized in

own, or one that is supplied by the study owners, patients can take

the future after the pandemic ends. Remote patient engagement and

advantage of a virtual assistant that is available to them 24/7, seven

monitoring technology has clear advantages to patient engagement,

days a week. This kind of technology can guide the patients through

recruitment, retention and data quality. These technologies promise

dosing, sending them alerts and reminders to ensure doses are not

to complement the important work study teams do in face-to-

missed. Doses can also be recorded in real time, with assistance from

face visits while simultaneously improving the value of those visits

advanced artificial intelligence that confirms correct dosage. The

through the provision of 24/7 patient data, allowing study teams to

study team then receives full visibility into dosing adherence across

focus on key issues versus basic data collection. Increasing patient

the patient pool, allowing them to track performance and identify

engagement through remote technologies has measurable impact

potential issues with patients quickly. Study teams can engage

on medication adherence and through this can improve the quality

remotely, via technology, with patients to help solve problems.

of data in clinical studies overall.

Patients feel supported through the ease of interacting with
caregivers, while the caregivers on the study team can solve problems
or prevent them entirely through simple and early interventions via
the remote technology.

References
1.	 Dejun Su, Tzeyu L. Michaud, Paul Estabrooks, Robert J. Schwab, Leslie A. Eiland, Geri
Hansen, Mary DeVany, Donglan Zhang, Yan Li, José A. Pagán, and Mohammad Siahpush.
Telemedicine and e-Health.Oct 2019.952-959.

Benefit 3: Easing Patient and Site Burden

2.	 Shiovitz TM, Bain EE, McCann DJ, et al. Mitigating the effects of nonadherence in clinical

The use of remote engagement and monitoring technology has the

3.	 Malhotra, et al. Patient Engagement Using New Technology to Improve Adherence to

potential to ease stress on patients, leading to better adherence and
overall study performance. Therapy regimens associated with clinical
trials can be complex. It can be a lot of additional work for patients
who are dealing with one or more illnesses while simultaneously
managing their careers and families. With a technology partner in
Pharmaceutical Outsourcing |

32

trials. J Clin Pharmacol 2016; 56(9): 1151-1164.
Positive Airway Pressure Therapy: A Retrospective Analysis. CHEST. Volume 153, Issue 4,
April 2018, Pages 843-850
4.	 Nipp, et al. Overcoming Barriers to Clinical Trial Enrollment. American Society of Clinical
Oncology Educational Book 39 (May 17, 2019) 105-114.
5.	 Forsythe, et al. Patient Engagement In Research: Early Findings From The Patient-Centered
Outcomes Research Institute. Health Affairs Vol. 38, No. 4. March 2019

| October/November/December 2020



PharmaceuticalOutsourcingQ42020

Table of Contents for the Digital Edition of PharmaceuticalOutsourcingQ42020

Editor's Message
Editorial Advisory Board
CN Perspectives
Social Media Connections
Insider Insight - Price
Insider Insight - Ventura
Contract Manufacturing
Supply Chain
Contract Manufacturing
Interview with Yourway
Supply Chain
Clinical Trials
Roundtable
Supply Chain
Analytical Testing
Supply Chain
Clinical Trials
Analytical Testing
Horizon Lines
Industry News
Advertiser's Index
PharmaceuticalOutsourcingQ42020 - Cover1
PharmaceuticalOutsourcingQ42020 - Cover2
PharmaceuticalOutsourcingQ42020 - 1
PharmaceuticalOutsourcingQ42020 - Editor's Message
PharmaceuticalOutsourcingQ42020 - 3
PharmaceuticalOutsourcingQ42020 - 4
PharmaceuticalOutsourcingQ42020 - 5
PharmaceuticalOutsourcingQ42020 - Editorial Advisory Board
PharmaceuticalOutsourcingQ42020 - 7
PharmaceuticalOutsourcingQ42020 - CN Perspectives
PharmaceuticalOutsourcingQ42020 - Social Media Connections
PharmaceuticalOutsourcingQ42020 - Insider Insight - Price
PharmaceuticalOutsourcingQ42020 - 11
PharmaceuticalOutsourcingQ42020 - Insider Insight - Ventura
PharmaceuticalOutsourcingQ42020 - 13
PharmaceuticalOutsourcingQ42020 - Contract Manufacturing
PharmaceuticalOutsourcingQ42020 - 15
PharmaceuticalOutsourcingQ42020 - 16
PharmaceuticalOutsourcingQ42020 - 17
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 19
PharmaceuticalOutsourcingQ42020 - Contract Manufacturing
PharmaceuticalOutsourcingQ42020 - 21
PharmaceuticalOutsourcingQ42020 - Interview with Yourway
PharmaceuticalOutsourcingQ42020 - 23
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 25
PharmaceuticalOutsourcingQ42020 - 26
PharmaceuticalOutsourcingQ42020 - 27
PharmaceuticalOutsourcingQ42020 - 28
PharmaceuticalOutsourcingQ42020 - 29
PharmaceuticalOutsourcingQ42020 - Clinical Trials
PharmaceuticalOutsourcingQ42020 - 31
PharmaceuticalOutsourcingQ42020 - 32
PharmaceuticalOutsourcingQ42020 - Roundtable
PharmaceuticalOutsourcingQ42020 - 34
PharmaceuticalOutsourcingQ42020 - 35
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 37
PharmaceuticalOutsourcingQ42020 - 38
PharmaceuticalOutsourcingQ42020 - 39
PharmaceuticalOutsourcingQ42020 - Analytical Testing
PharmaceuticalOutsourcingQ42020 - 41
PharmaceuticalOutsourcingQ42020 - 42
PharmaceuticalOutsourcingQ42020 - 43
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 45
PharmaceuticalOutsourcingQ42020 - 46
PharmaceuticalOutsourcingQ42020 - 47
PharmaceuticalOutsourcingQ42020 - Clinical Trials
PharmaceuticalOutsourcingQ42020 - 49
PharmaceuticalOutsourcingQ42020 - 50
PharmaceuticalOutsourcingQ42020 - Analytical Testing
PharmaceuticalOutsourcingQ42020 - 52
PharmaceuticalOutsourcingQ42020 - 53
PharmaceuticalOutsourcingQ42020 - Horizon Lines
PharmaceuticalOutsourcingQ42020 - 55
PharmaceuticalOutsourcingQ42020 - 56
PharmaceuticalOutsourcingQ42020 - 57
PharmaceuticalOutsourcingQ42020 - Industry News
PharmaceuticalOutsourcingQ42020 - 59
PharmaceuticalOutsourcingQ42020 - 60
PharmaceuticalOutsourcingQ42020 - 61
PharmaceuticalOutsourcingQ42020 - 62
PharmaceuticalOutsourcingQ42020 - 63
PharmaceuticalOutsourcingQ42020 - Advertiser's Index
PharmaceuticalOutsourcingQ42020 - Cover3
PharmaceuticalOutsourcingQ42020 - Cover4
https://www.nxtbook.com/comparenetworks/PharmaceuticalOutsourcing/po-q2-2021
https://www.nxtbook.com/comparenetworks/PharmaceuticalOutsourcing/PharmaceuticalOutsourcing2021CompanyFocus
https://www.nxtbook.com/comparenetworks/PharmaceuticalOutsourcing/PharmaceuticalOutsourcingQ42020
https://www.nxtbookmedia.com